MUSC first in state to monitor 'silent killer'
MUSC has become the first medical facility in South Carolina to use a new microchip sensor device in patients suffering from an often deadly arterial condition, aortic abdominal aneurysms (AAA). The sensor device enables monitoring without the need of surgery or intravenous (IV) dyes.MUSC vascular surgeon Bruce Elliott, M.D., and interventional radiologist Claudio Schonholz, M.D., also are the first in the state to implant an intraluminal pressure sensor device that allows the pressure inside a patient’s repaired aortic abdominal aneurysm to be monitored non-invasively.
“It’s absolutely ingenious,” said Elliott. “There
are no batteries, there’s no power supply. It’s simply a transducer
that’s commonly used in the automobile industry. It’s the same
sensor that detects the tire pressure in luxury cars.”
The key benefits of the procedure are that doctors can repeat monitoring more
often than with a CT scan. The procedure also is safer and potentially less
expensive that other methods.
By implanting a microchip with a graft into the aneurysm sac, doctors can
monitor the pressure with a sensor device that looks like a “high-tech
tennis racket,” Elliot said.
More than 200,000 Americans are diagnosed with AAA each year. AAA is a condition
in which the body’s largest artery becomes weakened and balloons or
bulges out from the arterial wall.
The condition often becomes a silent killer because patients typically show
no symptoms until an aneurysm ruptures. A person suffering from a ruptured
aneurysm has only a 10-percent to 20-percent chance of survival.
Treating the AAA condition prior to a rupture can reverse the 80-percent-to
90-percent fatality rate. As much as 98 percent of patients with AAA can be
successfully treated and cured of the condition, Elliot said.
The cure rate for AAA patients and opportunites for interention have grown
immensley, according to Elliott. “Left untreated, nearly all patients
with aortic aneurysms will die from their aneurysm ultimately,” he said.
“However, if treated, 95 percent will survive and can expect a near
normal life expectancy. This is significantly better than we can say we are
doing with many cancer survivals.”
The methods used to treat the condition have evolved through the years.
The first aortic aneurysm grafts were created in the early 1950s, literally
using a shirt tail that was sewn to make a graft and implanted into a patient.
These days, grafts are now made of strong manmade material, such as plastics
and fabrics, and shaped to the size of the healthy aorta, Elliott said.
In the traditional open surgery to repair an AAA, a large incision is made
in the abdominal wall from just below the patient’s breastbone to the
top of the pubic bone. The aortic graft is sewn to the healthy aortic tissue
above and below the weakened area so that, when finished, it functions as
a bridge for the blood flow.
The less invasive procedure began about 15 years ago. It involves doctors
implanting a stint graft intravascularly through the groin arteries. The stint
provides support for the wall and also helps retain an opening in the aortic
passage. During the early days using this procedure, stints would not work
in everyone, and they sometimes failed and had to be re-implanted. However
stint procedures have improved during the past six years. Medical advances
have made stint grafts possible in about 60 percent to 70 percent of patients,
and the early mortality rate has been cut in half, Elliott said.
“But there’s a downside,” Elliott said. “We’ve
got to follow those patients treated with Endovascular Aneurysm Repair (EVAR)
closely. They can’t just be operated on and dismissed from the practice.”
These patients, as long as the graft remains in place, are at some small but
increased risk of complications of this aortic aneurysm, including graft leakage,
migration, or aneurysm rupture.
Elliott explained that monitoring these repaired aneurysms usually requires
the patient to undergo two IV-contrast CT scans a year—for life. This
is not only costly, but the intravenous dye required for the CT scans can
be toxic to the kidneys in some patients. The microchip method substantially
reduces the concern for these issues.
The Catalyst Online
June 23, 2006
Catalyst Online is available at www.musc.edu/catalyst, published weekly, updated as needed and improved from time to time by the MUSC Office of Public Relations for the faculty, employees and students of the Medical University of South Carolina. Catalyst Online editor, Kim Draughn, can be reached at 792-4107 or by email, catalyst@musc.edu. Editorial copy can be submitted to Catalyst Online and to The Catalyst in print by fax, 792-6723, or by email to catalyst@musc.edu. To place an ad in The Catalyst hardcopy, call Island papers at 849-1778, ext. 201.

